24,247 Shares in LifeMD, Inc. (NASDAQ:LFMD) Bought by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC acquired a new position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 24,247 shares of the company's stock, valued at approximately $120,000. Sherbrooke Park Advisers LLC owned 0.06% of LifeMD as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of LFMD. Marshall Wace LLP lifted its holdings in LifeMD by 522.9% in the 4th quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock worth $1,839,000 after buying an additional 311,841 shares during the period. Royce & Associates LP raised its position in shares of LifeMD by 23.9% in the 4th quarter. Royce & Associates LP now owns 1,115,991 shares of the company's stock worth $5,524,000 after acquiring an additional 214,950 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of LifeMD by 21.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock worth $4,610,000 after acquiring an additional 165,378 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of LifeMD by 45.2% in the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company's stock worth $2,524,000 after acquiring an additional 158,796 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in shares of LifeMD by 825.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 158,423 shares of the company's stock worth $784,000 after acquiring an additional 141,307 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Price Performance

LFMD stock traded up $0.65 on Tuesday, reaching $12.18. 525,130 shares of the company traded hands, compared to its average volume of 973,648. LifeMD, Inc. has a one year low of $3.99 and a one year high of $12.18. The company has a market cap of $553.69 million, a P/E ratio of -19.04 and a beta of 2.22. The firm has a fifty day simple moving average of $6.95 and a 200-day simple moving average of $6.14.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million for the quarter, compared to the consensus estimate of $62.47 million. On average, sell-side analysts forecast that LifeMD, Inc. will post -0.56 EPS for the current year.

Insiders Place Their Bets

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of LifeMD stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.66, for a total value of $169,800.00. Following the completion of the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin Schreiber sold 21,995 shares of LifeMD stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $7.53, for a total value of $165,622.35. Following the completion of the sale, the chief executive officer now directly owns 2,553,726 shares of the company's stock, valued at approximately $19,229,556.78. The trade was a 0.85% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,995 shares of company stock valued at $724,422. Corporate insiders own 15.97% of the company's stock.

Analyst Upgrades and Downgrades

LFMD has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of LifeMD in a research report on Wednesday, April 30th. B. Riley raised LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $11.00.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.